Skip to main content

Market Overview

Biogen, Samsung JV Announces Etanercept Biosimilar Referencing Enbrel, BENEPALI, Approved in EU

Share:

The joint venture between Biogen
(NASDAQ: BIIB) and Samsung BioLogics, Samsung Bioepis, has been granted
European Commission (EC) approval for BENEPALI® , an
etanercept biosimilar referencing Enbrel®i. BENEPALI has been
granted marketing authorization in the European Union (EU) for the
treatment of adults with moderate to severe rheumatoid arthritis (RA),
psoriatic arthritis, non-radiographic axial spondyloarthritis and plaque
psoriasis. Biogen intends to make BENEPALI available for patients in the
coming weeks.

BENEPALI is the first etanercept biosimilar referencing Enbrel to be
approved in the EU, making it the first subcutaneous anti-TNF biosimilar
available there. Anti-TNF's are the largest component of the EU
biologics market, accounting for approximately $10 billion of

See full press release

 

Related Articles (BIIB)

View Comments and Join the Discussion!

Posted-In: News Press Releases

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com